AP828A - Process and crystal forms of 2-methyl-thieno-benzodiazepine. - Google Patents
Process and crystal forms of 2-methyl-thieno-benzodiazepine. Download PDFInfo
- Publication number
- AP828A AP828A APAP/P/1997/001065A AP9701065A AP828A AP 828 A AP828 A AP 828A AP 9701065 A AP9701065 A AP 9701065A AP 828 A AP828 A AP 828A
- Authority
- AP
- ARIPO
- Prior art keywords
- olanzapine
- polymorph
- active ingredient
- methyl
- ray powder
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40956695A | 1995-03-24 | 1995-03-24 | |
PCT/US1996/003917 WO1996030375A1 (en) | 1995-03-24 | 1996-03-22 | Process and crystal forms of 2-methyl-thieno-benzodiazepine |
Publications (2)
Publication Number | Publication Date |
---|---|
AP9701065A0 AP9701065A0 (en) | 1997-10-31 |
AP828A true AP828A (en) | 2000-04-28 |
Family
ID=23621056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
APAP/P/1997/001065A AP828A (en) | 1995-03-24 | 1996-03-22 | Process and crystal forms of 2-methyl-thieno-benzodiazepine. |
Country Status (49)
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EG23659A (en) * | 1995-03-24 | 2007-03-26 | Lilly Co Eli | Process and crystal forms of methyl-thieno-benzodiazepine |
CA2232559A1 (en) * | 1995-09-29 | 1997-04-03 | Charles Merritt Beasley Jr. | Method for treating a tic disorder |
UA57727C2 (uk) * | 1996-03-11 | 2003-07-15 | Елі Ліллі Енд Компані | Спосіб лікування надмірної агресивності |
EP0904083A4 (en) * | 1996-03-25 | 2002-05-22 | Lilly Co Eli | METHOD FOR ANESTHESIA |
PL329221A1 (en) * | 1996-03-25 | 1999-03-15 | Lilly Co Eli | Method of relieving hemicrania pains |
AU725556B2 (en) * | 1996-03-25 | 2000-10-12 | Eli Lilly And Company | Method for treating pain |
AU721338B2 (en) * | 1996-03-25 | 2000-06-29 | Eli Lilly And Company | Method for treating pain |
CZ299247B6 (cs) * | 1996-09-23 | 2008-05-28 | Eli Lilly And Company | Olanzapin dihydrát D |
ZA978515B (en) * | 1996-09-23 | 1999-03-23 | Lilly Co Eli | Intermediates and process for preparing olanzapine |
DK1155696T3 (da) * | 1997-04-15 | 2004-07-12 | Lilly Co Eli | Anvendelse af olanzapin til fremstillingen af et medikament til neurobeskyttelse |
WO1998046596A1 (en) * | 1997-04-15 | 1998-10-22 | Eli Lilly And Company | Method for providing neuro-protective effects |
US20030022889A1 (en) * | 1997-04-15 | 2003-01-30 | Bymaster Franklin P. | Method for providing neuro-protective effects |
ZA982917B (en) * | 1997-04-15 | 1999-10-06 | Lilly Co Eli | Method for treating cerebral focal stroke. |
USRE43932E1 (en) | 1997-07-18 | 2013-01-15 | Novartis Ag | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
US6617321B2 (en) | 1997-09-30 | 2003-09-09 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine formulation |
NZ510208A (en) * | 1998-09-30 | 2003-04-29 | Lilly Co Eli | Olanzapine (2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine) pamoate salt |
FR2802101B1 (fr) | 1999-12-10 | 2003-02-28 | Aventis Pharma Sa | Association de cymemazine et d'un neuroleptique atypique |
US7022698B2 (en) | 1999-12-28 | 2006-04-04 | U & I Pharmaceuticals, Ltd. | Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof |
US6348458B1 (en) | 1999-12-28 | 2002-02-19 | U & I Pharmaceuticals Ltd. | Polymorphic forms of olanzapine |
AU779452B2 (en) * | 1999-12-28 | 2005-01-27 | Cipla Limited | New polymorphic forms of olanzapine |
CA2420987A1 (en) * | 2000-08-31 | 2002-03-07 | Dr. Reddy's Laboratories Ltd. | Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine |
AU2001282913A1 (en) * | 2000-09-08 | 2002-03-22 | Eli Lilly And Company | A method of treating weight gain associated with atypical antipsychotic use |
US6740753B2 (en) | 2001-01-04 | 2004-05-25 | Geneva Pharmaceuticals, Inc. | Olanzapine crystal modification |
CA2464306A1 (en) * | 2001-10-29 | 2003-05-08 | Dr. Reddy's Laboratories Ltd. | Olanzapine dihydrate-ii a process for its preparation and use thereof |
CA2471341C (en) | 2001-12-24 | 2012-01-24 | Sun Pharmaceutical Industries Limited | Crystalline form i of 2-methyl-4-(4-methyl-1-piperazinyl) 10h thieno [2,3-b][1,5]benzodiazepine |
US7790905B2 (en) * | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
US20100311701A1 (en) * | 2002-02-15 | 2010-12-09 | Transform Pharmaceuticals, Inc | Pharmaceutical Co-Crystal Compositions |
WO2004089313A2 (en) * | 2003-04-01 | 2004-10-21 | Transform Pharmaceuticals, Inc. | Novel olanzapine forms and related methods of treatment |
EP2316468A1 (en) | 2002-02-22 | 2011-05-04 | Shire LLC | Delivery system and methods for protecting and administering dextroamphetamine |
EP1494998A2 (en) | 2002-03-01 | 2005-01-12 | University Of South Florida | Multiple-component solid phases containing at least one active pharmaceutical ingredient |
PL196814B1 (pl) * | 2002-05-17 | 2008-02-29 | Inst Farmaceutyczny | Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty |
AU2003237305A1 (en) * | 2002-05-31 | 2003-12-19 | Geneva Pharmaceuticals, Inc. | Process of preparation of olanzapine form i |
CA2489984A1 (en) * | 2002-06-21 | 2003-12-31 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions with improved dissolution |
SI21270A (sl) * | 2002-07-15 | 2004-02-29 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Kristalne oblike olanzapina in postopki za njihovo pripravo |
PL202856B1 (pl) * | 2002-12-20 | 2009-07-31 | Adamed Spo & Lstrok Ka Z Ogran | Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny |
US7323459B2 (en) | 2002-12-24 | 2008-01-29 | Teva Pharmaceutical Industries Ltd. | Crystal forms, methods for their preparation and method for preparation of olanzapine |
US8183290B2 (en) * | 2002-12-30 | 2012-05-22 | Mcneil-Ppc, Inc. | Pharmaceutically acceptable propylene glycol solvate of naproxen |
EP1507774A1 (en) * | 2003-03-12 | 2005-02-23 | Biogal Gyogyszergyar Rt. | Processes for preparation of polymorphic forms of desloratadine |
US20060135547A1 (en) * | 2003-03-12 | 2006-06-22 | Toth Zoltan G | Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine |
GB0314149D0 (en) * | 2003-06-18 | 2003-07-23 | Generics Uk Ltd | Novel amorphous forms |
GB0326148D0 (en) | 2003-11-10 | 2003-12-17 | Lilly Co Eli | Morpholine derivatives |
CA2546200A1 (en) * | 2003-11-18 | 2005-06-02 | 3M Innovative Properties Company | Olanzapine containing transdermal drug delivery compositions |
US7425627B2 (en) * | 2003-12-22 | 2008-09-16 | Teva Pharmaceutical Industries Ltd. | Methods of synthesizing olanzapine |
US20050272720A1 (en) * | 2004-01-27 | 2005-12-08 | Rolf Keltjens | Process for making olanzapine Form I |
DE602005027308D1 (de) | 2004-01-27 | 2011-05-19 | Synthon Bv | Stabile salze von olanzapin |
ES2253091B1 (es) | 2004-07-27 | 2007-02-01 | Inke, S.A. | Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo. |
WO2006027800A1 (en) * | 2004-09-06 | 2006-03-16 | Shasun Chemicals And Drugs Limited | A novel process for preparation of a pharmaceutically pure polymorphic form 1 of olanzapine |
BRPI0518187A (pt) * | 2004-11-16 | 2008-11-04 | Elan Pharma Int Ltd | formulações de olanzapina em nanopartìcula injetáveis |
EP1838716B1 (en) | 2005-01-05 | 2011-06-01 | Eli Lilly And Company | Olanzapine pamoate dihydrate |
CZ200563A3 (cs) * | 2005-02-02 | 2006-10-11 | Zentiva, A. S. | Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby |
US20100174066A1 (en) * | 2005-03-21 | 2010-07-08 | Venkataraman Sundaram | Process for preparing crystalline form i of olanzapine |
US20070021605A1 (en) * | 2005-07-20 | 2007-01-25 | Rolf Keltjens | Process and composition for making olanzapine form i |
WO2007020080A1 (en) * | 2005-08-17 | 2007-02-22 | Synthon B.V. | A process for making olanzapine form i |
GB0522474D0 (en) * | 2005-11-03 | 2005-12-14 | Actavis Group | A pharmaceutical formulation |
HUP0501046A2 (en) * | 2005-11-11 | 2007-08-28 | Egis Gyogyszergyar Nyilvanosan | Process for the preparation of olanzapine |
US8721202B2 (en) | 2005-12-08 | 2014-05-13 | Ncr Corporation | Two-sided thermal print switch |
US8367580B2 (en) | 2006-03-07 | 2013-02-05 | Ncr Corporation | Dual-sided thermal security features |
US8222184B2 (en) | 2006-03-07 | 2012-07-17 | Ncr Corporation | UV and thermal guard |
ES2279715B1 (es) | 2005-12-26 | 2008-06-01 | Laboratorios Lesvi, S.L. | Formulacion oral de olanzapina. |
US7834176B2 (en) | 2006-01-26 | 2010-11-16 | Sandoz Ag | Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E |
US20070293479A1 (en) * | 2006-05-18 | 2007-12-20 | Osinga Niels J | Olanzapine pharmaceutical composition |
CL2007002807A1 (es) * | 2006-09-29 | 2008-04-11 | Synthon Bv | Composicion farmaceutica en estado solido que comprende olanzapina o una sal farmaceuticamente aceptable de la misma y lactosa anhidra; tableta farmaceutica oral; procedimiento de preparacion de dicha tableta, util en el tratamiento de la esquizofren |
US7718649B1 (en) | 2006-11-10 | 2010-05-18 | Pisgah Labs, Inc. | Physical states of a pharmaceutical drug substance |
US8039461B1 (en) | 2006-11-10 | 2011-10-18 | Pisgah Laboratories, Inc. | Physical states of a pharmaceutical drug substance |
PL381564A1 (pl) | 2007-01-22 | 2008-08-04 | Koźluk Tomasz Nobilus Ent | Sposób wytwarzania zasadniczo czystej odmiany polimorficznej I olanzapiny |
CA2591644A1 (en) * | 2007-06-14 | 2008-12-14 | Apotex Pharmachem Inc. | Novel processes to form-i of olanzapine |
US9056488B2 (en) | 2007-07-12 | 2015-06-16 | Ncr Corporation | Two-side thermal printer |
US8883863B1 (en) | 2008-04-03 | 2014-11-11 | Pisgah Laboratories, Inc. | Safety of psuedoephedrine drug products |
CN101735239B (zh) * | 2008-11-06 | 2011-08-31 | 齐鲁制药有限公司 | 一种无水奥氮平晶型ii的制备方法 |
EP2292624A1 (en) | 2009-07-20 | 2011-03-09 | LEK Pharmaceuticals d.d. | Process for the purification of olanzapine |
HUE041981T2 (hu) | 2010-08-23 | 2019-06-28 | Alkermes Pharma Ireland Ltd | Eljárások antipszichotikum által kiváltott súlygyarapodás kezelésére |
CN102093386B (zh) * | 2011-01-05 | 2016-06-01 | 浙江华海药业股份有限公司 | 一种制备奥兰扎平晶型ⅱ的方法 |
WO2012153347A2 (en) | 2011-05-04 | 2012-11-15 | Zentiva K.S. | Oral pharmaceutical composition of olanzapine form 1 |
PL2888284T3 (pl) | 2012-08-21 | 2023-02-27 | Janssen Pharmaceutica Nv | Przeciwciała przeciwko haptenom rysperydonu i ich zastosowanie |
PT2887952T (pt) * | 2012-08-21 | 2019-08-30 | Janssen Pharmaceutica Nv | Anticorpos para haptenos da olanzapina e suas utilizações |
EP2888590B1 (en) | 2012-08-21 | 2020-07-08 | Janssen Pharmaceutica NV | Antibodies to olanzapine and use thereof |
EP2919788A4 (en) | 2012-11-14 | 2016-05-25 | Univ Johns Hopkins | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA |
CN103848847B (zh) * | 2012-12-04 | 2018-02-06 | 广东东阳光药业有限公司 | 一种改进制备奥氮平及其晶型ii的方法 |
JP6008734B2 (ja) * | 2012-12-20 | 2016-10-19 | 株式会社トクヤマ | オランザピンii型結晶の製造方法 |
CN103145731B (zh) * | 2013-02-26 | 2014-02-19 | 江苏豪森药业股份有限公司 | 奥氮平晶型及其制备方法和用途 |
WO2023139531A1 (en) | 2022-01-20 | 2023-07-27 | Teva Pharmaceuticals International Gmbh | Olanzapine, compositions thereof and methods of use thereof |
US20240238308A1 (en) | 2023-01-10 | 2024-07-18 | Medincell Sa | Olanzapine compositions and methods of use |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5229382A (en) * | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4115568A (en) * | 1974-11-26 | 1978-09-19 | Lilly Industries Limited | Thieno[3,2-b]-[1,5]benzodiazepines |
GB1548022A (en) | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
CA1097233A (en) | 1977-07-20 | 1981-03-10 | George K. E. Gregory | Packages |
US4237279A (en) * | 1979-07-27 | 1980-12-02 | Eli Lilly And Company | Crystalline 3-hydroxycephalosporin solvates |
IE53696B1 (en) | 1981-12-02 | 1989-01-18 | Wyeth John & Brother Ltd | Solid shaped articles |
US5039540A (en) | 1989-08-14 | 1991-08-13 | Neophore Technologies, Inc. | Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs |
US5079018A (en) | 1989-08-14 | 1992-01-07 | Neophore Technologies, Inc. | Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs |
GB9009229D0 (en) * | 1990-04-25 | 1990-06-20 | Lilly Industries Ltd | Pharmaceutical compounds |
PT582368E (pt) * | 1992-05-29 | 2001-05-31 | Lilly Co Eli | Derivados de tienobenzodiazepina para o tratamento de doencas de cns |
US5439888A (en) * | 1994-03-04 | 1995-08-08 | Eli Lilly And Company | Antithrombotic agents |
US5457101A (en) * | 1994-06-03 | 1995-10-10 | Eli Lilly And Company | Thieno[1,5]benzoidiazepine use |
EG23659A (en) * | 1995-03-24 | 2007-03-26 | Lilly Co Eli | Process and crystal forms of methyl-thieno-benzodiazepine |
-
1996
- 1996-03-21 EG EG19960250A patent/EG23659A/xx active
- 1996-03-22 TW TW085103500A patent/TW442488B/zh not_active IP Right Cessation
- 1996-03-22 ES ES00203573T patent/ES2208220T3/es not_active Expired - Lifetime
- 1996-03-22 CN CN96192775A patent/CN1065536C/zh not_active Expired - Lifetime
- 1996-03-22 SI SI9630345T patent/SI0733635T1/xx unknown
- 1996-03-22 PL PL96322501A patent/PL183723B1/pl not_active IP Right Cessation
- 1996-03-22 SI SI9620040A patent/SI9620040B/sl not_active IP Right Cessation
- 1996-03-22 AT AT0902196A patent/AT406771B/de not_active IP Right Cessation
- 1996-03-22 AP APAP/P/1997/001065A patent/AP828A/en active
- 1996-03-22 DE DE19681286T patent/DE19681286T1/de not_active Withdrawn
- 1996-03-22 LU LU90096A patent/LU90096B1/fr active
- 1996-03-22 NZ NZ306110A patent/NZ306110A/en not_active IP Right Cessation
- 1996-03-22 BR BR9607790A patent/BR9607790A/pt not_active IP Right Cessation
- 1996-03-22 GB GB9719819A patent/GB2313835B/en not_active Expired - Fee Related
- 1996-03-22 CA CA002214005A patent/CA2214005C/en not_active Expired - Fee Related
- 1996-03-22 CZ CZ19973000A patent/CZ292688B6/cs not_active IP Right Cessation
- 1996-03-22 AU AU54279/96A patent/AU706471B2/en not_active Ceased
- 1996-03-22 IL IL11761096A patent/IL117610A/xx not_active IP Right Cessation
- 1996-03-22 EP EP96302000A patent/EP0733635B1/en not_active Expired - Lifetime
- 1996-03-22 JP JP8529532A patent/JPH11502535A/ja not_active Ceased
- 1996-03-22 SI SI9630636T patent/SI1095941T1/xx unknown
- 1996-03-22 KR KR1019970706591A patent/KR100399688B1/ko not_active IP Right Cessation
- 1996-03-22 EP EP03077455A patent/EP1445259B1/en not_active Expired - Lifetime
- 1996-03-22 DE DE69614426T patent/DE69614426T2/de not_active Expired - Lifetime
- 1996-03-22 DK DK96302000T patent/DK0733635T3/da active
- 1996-03-22 YU YU17796A patent/YU49478B/sh unknown
- 1996-03-22 ES ES03077455T patent/ES2266719T3/es not_active Expired - Lifetime
- 1996-03-22 DE DE69630324T patent/DE69630324T2/de not_active Expired - Lifetime
- 1996-03-22 CO CO96014567A patent/CO4650278A1/es unknown
- 1996-03-22 PT PT03077455T patent/PT1445259E/pt unknown
- 1996-03-22 AT AT03077455T patent/ATE331719T1/de active
- 1996-03-22 AT AT96302000T patent/ATE204280T1/de active
- 1996-03-22 TW TW085103499A patent/TW513432B/zh not_active IP Right Cessation
- 1996-03-22 EE EE9700232A patent/EE03489B1/et not_active IP Right Cessation
- 1996-03-22 DE DE69636313T patent/DE69636313T2/de not_active Expired - Lifetime
- 1996-03-22 WO PCT/US1996/003917 patent/WO1996030375A1/en active IP Right Grant
- 1996-03-22 UA UA97094737A patent/UA44765C2/uk unknown
- 1996-03-22 PT PT96302000T patent/PT733635E/pt unknown
- 1996-03-22 DK DK03077455T patent/DK1445259T3/da active
- 1996-03-22 SK SK1218-97A patent/SK284143B6/sk not_active IP Right Cessation
- 1996-03-22 AT AT00203573T patent/ATE251627T1/de active
- 1996-03-22 AR ARP960101875A patent/AR010448A1/es unknown
- 1996-03-22 EP EP00203573A patent/EP1095941B1/en not_active Expired - Lifetime
- 1996-03-22 PE PE1996000203A patent/PE44897A1/es not_active IP Right Cessation
- 1996-03-22 PT PT00203573T patent/PT1095941E/pt unknown
- 1996-03-22 TR TR97/01017T patent/TR199701017T1/xx unknown
- 1996-03-22 SI SI9630743T patent/SI1445259T1/sl unknown
- 1996-03-22 CH CH02245/97A patent/CH690579A5/de not_active IP Right Cessation
- 1996-03-22 EA EA199700262A patent/EA000149B1/ru not_active IP Right Cessation
- 1996-03-22 HU HU9802824A patent/HU224989B1/hu not_active IP Right Cessation
- 1996-03-22 ZA ZA9602342A patent/ZA962342B/xx unknown
- 1996-03-22 ZA ZA9602344A patent/ZA962344B/xx unknown
- 1996-03-22 DK DK00203573T patent/DK1095941T3/da active
- 1996-03-22 ES ES96302000T patent/ES2159346T3/es not_active Expired - Lifetime
- 1996-03-22 RO RO97-01761A patent/RO118872B1/ro unknown
- 1996-03-22 MY MYPI96001085A patent/MY114701A/en unknown
- 1996-03-22 AR ARP960101876A patent/AR002719A1/es unknown
- 1996-05-09 SV SV1996000031A patent/SV1996000031A/es not_active Application Discontinuation
- 1996-07-25 US US08/686,989 patent/US5736541A/en not_active Expired - Lifetime
- 1996-10-18 PA PA19968353701A patent/PA8353701A1/es unknown
-
1997
- 1997-09-05 SE SE9703205A patent/SE9703205D0/xx not_active Application Discontinuation
- 1997-09-08 LV LVP-97-163A patent/LV12018B/en unknown
- 1997-09-16 LT LT97-148A patent/LT4349B/lt not_active IP Right Cessation
- 1997-09-22 IS IS4564A patent/IS1896B/is unknown
- 1997-09-22 FI FI973750A patent/FI973750A0/fi unknown
- 1997-09-22 BG BG101900A patent/BG62619B1/bg unknown
- 1997-09-22 NO NO19974365A patent/NO314663B1/no not_active IP Right Cessation
- 1997-09-23 DK DK108997A patent/DK108997A/da not_active Application Discontinuation
- 1997-09-24 OA OA70082A patent/OA10510A/en unknown
-
1998
- 1998-12-23 HK HK98115175A patent/HK1013988A1/xx not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5229382A (en) * | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP828A (en) | Process and crystal forms of 2-methyl-thieno-benzodiazepine. | |
AU720366B2 (en) | Olanzapine dihydrate D | |
EP0828494A1 (en) | Method for treating cognitive dysfunction | |
MXPA97007183A (en) | A process and glass forms of 2-methyl-tieno-benzodiazep | |
US6506746B2 (en) | Method for treating cognitive dysfunction | |
NZ325035A (en) | Method for treating excessive aggression using olanzapine |